JP2020022483A5 - - Google Patents

Download PDF

Info

Publication number
JP2020022483A5
JP2020022483A5 JP2019190648A JP2019190648A JP2020022483A5 JP 2020022483 A5 JP2020022483 A5 JP 2020022483A5 JP 2019190648 A JP2019190648 A JP 2019190648A JP 2019190648 A JP2019190648 A JP 2019190648A JP 2020022483 A5 JP2020022483 A5 JP 2020022483A5
Authority
JP
Japan
Prior art keywords
modified oligonucleotide
pharmaceutical composition
pharmaceutically acceptable
pbs
buffered saline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019190648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020022483A (ja
JP6924242B2 (ja
Filing date
Publication date
Priority claimed from JP2017546618A external-priority patent/JP6606557B2/ja
Application filed filed Critical
Publication of JP2020022483A publication Critical patent/JP2020022483A/ja
Publication of JP2020022483A5 publication Critical patent/JP2020022483A5/ja
Priority to JP2021124953A priority Critical patent/JP2021184720A/ja
Application granted granted Critical
Publication of JP6924242B2 publication Critical patent/JP6924242B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019190648A 2015-04-16 2019-10-18 C9orf72発現を調節するための組成物 Expired - Fee Related JP6924242B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021124953A JP2021184720A (ja) 2015-04-16 2021-07-30 C9orf72発現を調節するための組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562148691P 2015-04-16 2015-04-16
US62/148,691 2015-04-16
US201562232941P 2015-09-25 2015-09-25
US62/232,941 2015-09-25
US201562239400P 2015-10-09 2015-10-09
US62/239,400 2015-10-09
JP2017546618A JP6606557B2 (ja) 2015-04-16 2016-04-15 C9orf72発現を調節するための組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017546618A Division JP6606557B2 (ja) 2015-04-16 2016-04-15 C9orf72発現を調節するための組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021124953A Division JP2021184720A (ja) 2015-04-16 2021-07-30 C9orf72発現を調節するための組成物

Publications (3)

Publication Number Publication Date
JP2020022483A JP2020022483A (ja) 2020-02-13
JP2020022483A5 true JP2020022483A5 (enExample) 2020-05-14
JP6924242B2 JP6924242B2 (ja) 2021-08-25

Family

ID=57126261

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017546618A Expired - Fee Related JP6606557B2 (ja) 2015-04-16 2016-04-15 C9orf72発現を調節するための組成物
JP2019190648A Expired - Fee Related JP6924242B2 (ja) 2015-04-16 2019-10-18 C9orf72発現を調節するための組成物
JP2021124953A Ceased JP2021184720A (ja) 2015-04-16 2021-07-30 C9orf72発現を調節するための組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017546618A Expired - Fee Related JP6606557B2 (ja) 2015-04-16 2016-04-15 C9orf72発現を調節するための組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021124953A Ceased JP2021184720A (ja) 2015-04-16 2021-07-30 C9orf72発現を調節するための組成物

Country Status (30)

Country Link
US (4) US9605263B2 (enExample)
EP (2) EP3283080B1 (enExample)
JP (3) JP6606557B2 (enExample)
KR (2) KR102104163B1 (enExample)
CN (2) CN113265404A (enExample)
AU (2) AU2016249002B2 (enExample)
BR (1) BR112017016068A2 (enExample)
CA (1) CA2978103A1 (enExample)
CL (4) CL2017002567A1 (enExample)
CO (1) CO2017007671A2 (enExample)
CY (1) CY1122981T1 (enExample)
DK (1) DK3283080T3 (enExample)
ES (1) ES2791995T3 (enExample)
HR (1) HRP20200843T1 (enExample)
HU (1) HUE049233T2 (enExample)
IL (2) IL253557B (enExample)
LT (1) LT3283080T (enExample)
MX (2) MX366128B (enExample)
MY (1) MY181815A (enExample)
NZ (1) NZ733882A (enExample)
PH (2) PH12017501875B1 (enExample)
PL (1) PL3283080T3 (enExample)
PT (1) PT3283080T (enExample)
RS (1) RS60230B1 (enExample)
RU (1) RU2736574C2 (enExample)
SA (3) SA520412451B1 (enExample)
SG (2) SG11201708468YA (enExample)
SI (1) SI3283080T1 (enExample)
SM (1) SMT202000165T1 (enExample)
WO (1) WO2016168592A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
US9744183B2 (en) 2009-07-06 2017-08-29 Wave Life Sciences Ltd. Nucleic acid prodrugs and methods of use thereof
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
RU2014105311A (ru) 2011-07-19 2015-08-27 Уэйв Лайф Сайенсес Пте. Лтд. Способы синтеза функционализованных нуклеиновых кислот
PT2872485T (pt) 2012-07-13 2021-03-05 Wave Life Sciences Ltd Grupo auxiliar assimétrico
EP2906697A4 (en) 2012-10-15 2016-06-22 Ionis Pharmaceuticals Inc METHOD FOR MONITORING THE C9ORF72 EXPRESSION
EP2906696B2 (en) 2012-10-15 2022-12-14 Ionis Pharmaceuticals, Inc. Methods for modulating c9orf72 expression
US10443052B2 (en) 2012-10-15 2019-10-15 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
US10221414B2 (en) 2013-10-11 2019-03-05 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
PT3094728T (pt) 2014-01-16 2022-05-19 Wave Life Sciences Ltd Desenho quiral
WO2017079291A1 (en) 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating c90rf72
CA3017532A1 (en) * 2016-04-13 2017-10-19 Ionis Pharmaceuticals, Inc. Methods for reducing c9orf72 expression
WO2018081728A1 (en) * 2016-10-31 2018-05-03 Emendobio Inc. Compositions for genome editing
US20200362337A1 (en) 2017-08-08 2020-11-19 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
US10905707B2 (en) 2017-11-10 2021-02-02 University Of Massachusetts Compositions and methods for the treatment of expanded repeat-associated disorders
CA3088112A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
BR112020014011A2 (pt) 2018-01-12 2020-12-08 Bristol-Myers Squibb Company Oligonucleotídeos antissenso dirigidos à alfa-sinucleína e usos dos mesmos
CA3107352A1 (en) * 2018-07-23 2020-01-30 Enclear Therapies, Inc. Methods of treating neurological disorders
US20210317455A1 (en) 2018-08-03 2021-10-14 National University Corporation Tokyo Medical And Dental University Inhibitor of tdp-43 aggregation
WO2020106996A1 (en) * 2018-11-21 2020-05-28 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing prion expression
MX2021006548A (es) 2018-12-06 2021-09-21 Biogen Ma Inc Proteina de neurofilamento para guiar la intervencion terapeutica en la esclerosis lateral amiotrofica.
AU2020252020A1 (en) * 2019-03-29 2021-11-11 University Of Massachusetts Oligonucleotide-based modulation of C90RF72
EP3966328A4 (en) * 2019-05-06 2023-10-18 University Of Massachusetts Anti-c9orf72 oligonucleotides and related methods
US20240175016A1 (en) * 2019-10-06 2024-05-30 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2024036186A2 (en) * 2022-08-09 2024-02-15 The University Of Massachusetts Identification of allele-specific target sequences for c9orf72

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
EP0497875B1 (en) 1989-10-24 2000-03-22 Isis Pharmaceuticals, Inc. 2' modified oligonucleotides
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ES2116977T3 (es) 1990-05-11 1998-08-01 Microprobe Corp Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente.
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
DE59208572D1 (de) 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
DE69233599T2 (de) 1991-12-24 2006-12-14 Isis Pharmaceuticals, Inc., Carlsbad Unterbrochene 2'-modifizierte Oligonukleotide
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
EP0691968B1 (en) 1993-03-30 1997-07-16 Sanofi Acyclic nucleoside analogs and oligonucleotide sequences containing them
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5681940A (en) * 1994-11-02 1997-10-28 Icn Pharmaceuticals Sugar modified nucleosides and oligonucleotides
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
CA2303299C (en) 1997-09-12 2016-02-23 Exiqon A/S Oligonucleotide analogues
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6043352A (en) 1998-08-07 2000-03-28 Isis Pharmaceuticals, Inc. 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
US5998148A (en) 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
DE60033927T2 (de) 1999-05-04 2007-11-29 Santaris Pharma A/S L-ribo-lna analoge
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
ATE322493T1 (de) 1999-12-30 2006-04-15 Leuven K U Res & Dev Cyclohexennukleinsäuren
USH2191H1 (en) 2000-10-24 2007-06-05 Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
US20050019915A1 (en) 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
JP2005504020A (ja) 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド ヌクレアーゼ耐性キメラオリゴヌクレオチド
AU2003290596B2 (en) 2002-11-05 2011-05-12 Isis Pharmaceuticals, Inc. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
EP2314691A3 (en) 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7217807B2 (en) 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ, インコーポレーテッド 4’−チオヌクレオシドおよびオリゴマー化合物
US20050261233A1 (en) 2004-04-21 2005-11-24 Sanjay Bhanot Modulation of glucose-6-phosphatase translocase expression
CN101052717A (zh) 2004-05-11 2007-10-10 α基因株式会社 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法
EP1765416A4 (en) 2004-06-03 2010-03-24 Isis Pharmaceuticals Inc DOUBLE-STRONG COMPOSITIONS WITH DIFFERENTLY MODIFIED STRANDS FOR USE IN GENE MODULATION
CA2569036A1 (en) 2004-06-03 2005-12-22 Balkrishen Bhat Chimeric gapped oligomeric compositions
EP1812569A2 (en) 2004-11-08 2007-08-01 K.U. Leuven Research and Development Modified nucleosides for rna interference
EP3210633B1 (en) 2006-01-26 2019-06-19 Ionis Pharmaceuticals, Inc. Compositions and their uses directed to huntingtin
PL2314594T3 (pl) 2006-01-27 2014-12-31 Isis Pharmaceuticals Inc Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych
DK2363481T3 (en) 2006-05-05 2017-06-26 Ionis Pharmaceuticals Inc Compounds and methods for modulating gene expression
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US20100216864A1 (en) 2006-10-09 2010-08-26 Ellen Marie Straarup RNA Antagonist Compounds for the Modulation of PCSK9
CN102604951A (zh) 2006-12-14 2012-07-25 诺瓦提斯公司 治疗肌肉和心血管病症的组合物和方法
US20100190837A1 (en) 2007-02-15 2010-07-29 Isis Pharmaceuticals, Inc. 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
US8278426B2 (en) 2007-06-08 2012-10-02 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
ATE462787T1 (de) 2007-06-18 2010-04-15 Commissariat Energie Atomique Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington
CA2692579C (en) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
US20090123928A1 (en) 2007-10-11 2009-05-14 The Johns Hopkins University Genomic Landscapes of Human Breast and Colorectal Cancers
JP2011502502A (ja) * 2007-11-05 2011-01-27 バルティック テクロノジー デヴェロプメント,リミテッド 核酸のハイブリッド形成における修飾塩基を含むオリゴヌクレオチドの使用
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
EP2265627A2 (en) 2008-02-07 2010-12-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
EP2356129B1 (en) 2008-09-24 2013-04-03 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
WO2010036696A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Cyclohexenyl nucleic acid analogs
US20120149757A1 (en) 2009-04-13 2012-06-14 Krainer Adrian R Compositions and methods for modulation of smn2 splicing
CA2758927A1 (en) * 2009-04-15 2010-10-21 Isis Pharmaceuticals, Inc. Modulation of inflammatory responses by factor xi
KR20120050429A (ko) 2009-06-15 2012-05-18 알닐람 파마슈티칼스 인코포레이티드 Pcsk9 유전자를 표적으로 하는 지질 제형된 dsrna
JP2014501489A (ja) 2009-07-06 2014-01-23 アルナイラム ファーマシューティカルズ, インコーポレイテッド 細胞ベースのバイオプロセシング
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
WO2011017521A2 (en) 2009-08-06 2011-02-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
WO2011135396A1 (en) 2010-04-30 2011-11-03 Cellectis Method for modulating double-strand break-induced homologous recombination
WO2012005898A2 (en) 2010-06-15 2012-01-12 Alnylam Pharmaceuticals, Inc. Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof
EP3031920B1 (en) * 2010-07-19 2019-08-21 Ionis Pharmaceuticals, Inc. Modulation of dystrophia myotonica-protein kinase (dmpk) expression
AU2011329777B2 (en) * 2010-11-17 2016-06-09 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
EP2655621B1 (en) 2010-12-20 2018-05-23 The General Hospital Corporation Polycomb-associated non-coding rnas
WO2012092367A1 (en) 2010-12-28 2012-07-05 University Of Rochester Nucleic acid binding compounds, methods of making, and use thereof
SG193504A1 (en) * 2011-04-01 2013-10-30 Isis Pharmaceuticals Inc Modulation of signal transducer and activator of transcription 3 (stat3) expression
SI3505528T1 (sl) * 2011-04-21 2021-04-30 Glaxo Group Limited Modulacija izražanja virusa hepatitisa B (HBV)
US9896729B2 (en) 2011-08-31 2018-02-20 The University Of Manchester Method for diagnosing a neurodegenerative disease
US20140255936A1 (en) 2011-09-09 2014-09-11 Mayo Foundation For Medical Education And Research Detecting frontotemporal dementia and amyotrophic lateral sclerosis
WO2013063313A1 (en) * 2011-10-25 2013-05-02 Isis Pharmaceuticals, Inc. Antisense modulation of gccr expression
AU2012340118A1 (en) * 2011-11-17 2014-04-24 Rheonix, Inc. System and methods for selective molecular analysis
ES2832531T3 (es) * 2011-11-30 2021-06-10 Sarepta Therapeutics Inc Oligonucleótidos para el tratamiento de enfermedades por expansión de repeticiones
WO2013086207A1 (en) 2011-12-06 2013-06-13 The Ohio State University Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease
ES2639066T3 (es) 2012-04-23 2017-10-25 Biomarin Technologies B.V. Oligonucleótidos de modulación de ARN con características mejoradas para el tratamiento de trastornos neuromusculares
KR20170142997A (ko) * 2012-05-24 2017-12-28 아이오니스 파마수티컬즈, 인코포레이티드 아포지질단백질 (a) 발현을 조절하는 방법들 및 조성물들
US10443052B2 (en) * 2012-10-15 2019-10-15 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
EP2906697A4 (en) * 2012-10-15 2016-06-22 Ionis Pharmaceuticals Inc METHOD FOR MONITORING THE C9ORF72 EXPRESSION
EP2906696B2 (en) 2012-10-15 2022-12-14 Ionis Pharmaceuticals, Inc. Methods for modulating c9orf72 expression
ES2744804T3 (es) * 2013-01-22 2020-02-26 Deutsches Zentrum Fuer Neurodegenerative Erkrankungen E V Proteínas de repetición de dipéptidos como objetivo terapéutico en enfermedades neurodegenerativas con expansión de repetición de hexanucleótidos
US10221414B2 (en) 2013-10-11 2019-03-05 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
WO2016024205A1 (en) 2014-08-15 2016-02-18 Pfizer Inc. Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
WO2016060919A1 (en) 2014-10-14 2016-04-21 The Board Of Regents Of The University Of Texas System Allele selective inhibition of mutant c9orf72 foci expression by duplex rnas targeting the expanded hexanucleotide repeat
WO2017079291A1 (en) 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating c90rf72
CA3017532A1 (en) 2016-04-13 2017-10-19 Ionis Pharmaceuticals, Inc. Methods for reducing c9orf72 expression
US10399845B2 (en) 2017-09-22 2019-09-03 Emco Wheaton Retail Corporation Testable overfill prevention valve for a liquid storage container

Similar Documents

Publication Publication Date Title
JP2020022483A5 (enExample)
JP2020058368A5 (enExample)
JP2016116520A5 (enExample)
JP2017513469A5 (enExample)
JP2018199700A5 (enExample)
RU2017139121A (ru) Композиции для модулирования экспрессии c9orf72
JP2012505660A5 (enExample)
JP2019088329A5 (enExample)
JP2019512498A5 (enExample)
JP2021074021A5 (enExample)
JP2017536366A5 (enExample)
JP2021072840A5 (enExample)
JP2017505623A5 (enExample)
JP2017536119A5 (enExample)
JP2019062913A5 (enExample)
JP2014521310A5 (enExample)
JP2018530560A5 (enExample)
JP2016513976A5 (enExample)
JP2014530004A5 (enExample)
JP2019141097A5 (enExample)
JP2007504830A5 (enExample)
JP2016502858A5 (enExample)
RU2016116849A (ru) Композиции для модуляции экспрессии c90rf72
JP2012050438A5 (enExample)
JP2020522244A5 (enExample)